gemfibrozil has been researched along with Polymyositis in 2 studies
Polymyositis: Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| " It is unclear if polymyositis was triggered by interaction of the statin with omeprazole and/or gemfibrozil, or if it developed secondary to long-term use of atorvastatin only." | 5.39 | Statin-associated polymyositis following omeprazole treatment. ( Flores, RM; Kanth, R; Shah, MS, 2013) |
| "Statin monotherapy is generally well tolerated, with a low frequency of adverse events." | 2.42 | Safety of statins: focus on clinical pharmacokinetics and drug interactions. ( Bellosta, S; Corsini, A; Paoletti, R, 2004) |
| " It is unclear if polymyositis was triggered by interaction of the statin with omeprazole and/or gemfibrozil, or if it developed secondary to long-term use of atorvastatin only." | 1.39 | Statin-associated polymyositis following omeprazole treatment. ( Flores, RM; Kanth, R; Shah, MS, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanth, R | 1 |
| Shah, MS | 1 |
| Flores, RM | 1 |
| Bellosta, S | 1 |
| Paoletti, R | 1 |
| Corsini, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Liver Injury by Statins in Coronary Heart Disease (CHD) Patients With History of Hepatitis B Virus (HBV) Infection[NCT02808299] | 600 participants (Anticipated) | Observational | 2016-12-31 | Not yet recruiting | |||
| A Multicenter Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)[NCT01152073] | 79 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for gemfibrozil and Polymyositis
| Article | Year |
|---|---|
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced L | 2004 |
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced L | 2004 |
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced L | 2004 |
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced L | 2004 |
1 other study available for gemfibrozil and Polymyositis
| Article | Year |
|---|---|
Statin-associated polymyositis following omeprazole treatment.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Interactions; Esophagitis; Gemfibrozil; Heptanoic Acids | 2013 |